Pierrel S.p.A. entered into agreements to acquire from 3M Company contracts, permits and intellectual property related to the local anaesthesia dental products, together with related syringe and needle products, under the brands Ubistesin™, Xylestesin™ and Mepivastesin™ for a purchase price of USD 70 million
• The acquisition will expand Pierrel’s presence globally with branded products by complementing its own-brand dental anesthetics Orabloc’s offering, bringing more solutions to Pierrel’s customers.
• Pierrel’s revenues for FY 2024 is expected to double compared to the estimated revenues for the current year.
Capua (Italy), May 2th 2023 - Pierrel S.p.A. (“Pierrel”), global provider of services for the pharmaceutical industry focused in the development, production, registration and licensing of synthetic drugs, local anaesthetics and medical devices for the oral care sector, authorized by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) and whose shares are listed on the Euronext Milan market organised and managed by Borsa Italiana S.p.A. (EXM: PRL), announced today the signing of agreements with 3M Company.........READ MORE
Ultradent Products, Inc., a leading developer and manufacturer of high-tech dental materials, today released its newest product, J-Tempâ„¢ temporary resin, a premixed, ligh...
Hangzhou, China, 7 March 2023Â - SHINING 3D has just unveiled 3 brand new products that will enhance its range of digital dentistry solutions. SHINING 3D offers scannin...
People are seeking dental treatments, including tooth fillings, to address aesthetic concerns such as tooth discoloration, gaps, or visible decay. Tooth filling materials...
Pierrel S.p.A. entered into agreements to acquire from 3M Company contracts, permits and intellectual property related to the local anaesthesia dental products, together...
A virtual marketplace leading your business into the future